FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016308382> ?p ?o ?g. }

• W2016308382 endingPage "137" @default.
• W2016308382 startingPage "131" @default.
• W2016308382 abstract "Our purpose was to clarify the clinical utility of identifying metabolic syndrome (MetS) in patients with coronary artery disease (CAD).It is uncertain whether MetS influences prognosis in patients with CAD and whether the risk associated with MetS exceeds the risk associated with the sum of its individual components.In a post hoc analysis, we compared the incidence of death or myocardial infarction (MI) in stable CAD patients in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial according to the presence (+) or absence (-) of MetS and diabetes: Group A, -MetS/-diabetes; Group B, +MetS/-diabetes; Group C, -MetS/+diabetes; and Group D, +MetS/+diabetes. We explored which MetS components best predicted adverse outcomes and whether MetS had independent prognostic significance beyond its individual components.Of 2,248 patients, 61% had MetS and 34% diabetes. Risk for death or MI increased from Group A (14%) to Group D (25%, p < 0.001). Hypertension (hazard ratio [HR]: 1.30; 95% confidence interval [CI]: 0.98 to 1.71; p = 0.07), low high-density lipoprotein cholesterol (HR: 1.26; 95% CI: 1.03 to 1.55; p = 0.03), and elevated glucose (HR: 1.17; 95% CI: 0.96 to 1.47; p = 0.11) most strongly predicted death or MI. MetS was associated with an increased risk of death or MI (unadjusted HR: 1.41; 95% CI: 1.15 to 1.73; p = 0.001). However, after adjusting for its individual components, MetS was no longer significantly associated with outcome (HR: 1.15; 95% CI: 0.79 to 1.68; p = 0.46). Allocation to initial percutaneous coronary intervention did not affect the incidence of death or MI within any group.Among stable CAD patients in the COURAGE trial, the presence of MetS identified increased risk for death or MI, but MetS did not have independent prognostic significance after adjusting for its constituent components. The addition of early percutaneous coronary intervention to optimal medical therapy did not significantly reduce the risk of death or MI regardless of MetS or diabetes status. (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE]; NCT00007657)." @default.
• W2016308382 created "2016-06-24" @default.
• W2016308382 creator A5000653451 @default.
• W2016308382 creator A5015021993 @default.
• W2016308382 creator A5020886020 @default.
• W2016308382 creator A5021558981 @default.
• W2016308382 creator A5024418476 @default.
• W2016308382 creator A5033386949 @default.
• W2016308382 creator A5050936489 @default.
• W2016308382 creator A5051674313 @default.
• W2016308382 creator A5052993534 @default.
• W2016308382 creator A5062520509 @default.
• W2016308382 creator A5068433367 @default.
• W2016308382 creator A5069006768 @default.
• W2016308382 creator A5072408201 @default.
• W2016308382 creator A5085163310 @default.
• W2016308382 date "2011-07-01" @default.
• W2016308382 modified "2023-10-17" @default.
• W2016308382 title "Impact of Metabolic Syndrome and Diabetes on Prognosis and Outcomes With Early Percutaneous Coronary Intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial" @default.
• W2016308382 cites W109149758 @default.
• W2016308382 cites W1525697383 @default.
• W2016308382 cites W184028435 @default.
• W2016308382 cites W1983273787 @default.
• W2016308382 cites W1994115819 @default.
• W2016308382 cites W2010792860 @default.
• W2016308382 cites W2035943194 @default.
• W2016308382 cites W2038057193 @default.
• W2016308382 cites W2053834460 @default.
• W2016308382 cites W2060449981 @default.
• W2016308382 cites W2067156849 @default.
• W2016308382 cites W2108362443 @default.
• W2016308382 cites W2119513877 @default.
• W2016308382 cites W2120862552 @default.
• W2016308382 cites W2123289485 @default.
• W2016308382 cites W2129244743 @default.
• W2016308382 cites W2129448542 @default.
• W2016308382 cites W2132083141 @default.
• W2016308382 cites W2138851476 @default.
• W2016308382 cites W2142179136 @default.
• W2016308382 cites W2145461726 @default.
• W2016308382 cites W2147756578 @default.
• W2016308382 cites W2156121263 @default.
• W2016308382 cites W2160414137 @default.
• W2016308382 cites W2169121622 @default.
• W2016308382 cites W4238251256 @default.
• W2016308382 doi "https://doi.org/10.1016/j.jacc.2011.02.046" @default.
• W2016308382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21718908" @default.
• W2016308382 hasPublicationYear "2011" @default.
• W2016308382 type Work @default.
• W2016308382 sameAs 2016308382 @default.
• W2016308382 citedByCount "45" @default.
• W2016308382 countsByYear W20163083822012 @default.
• W2016308382 countsByYear W20163083822013 @default.
• W2016308382 countsByYear W20163083822014 @default.
• W2016308382 countsByYear W20163083822015 @default.
• W2016308382 countsByYear W20163083822016 @default.
• W2016308382 countsByYear W20163083822017 @default.
• W2016308382 countsByYear W20163083822018 @default.
• W2016308382 countsByYear W20163083822019 @default.
• W2016308382 countsByYear W20163083822020 @default.
• W2016308382 countsByYear W20163083822021 @default.
• W2016308382 countsByYear W20163083822023 @default.
• W2016308382 crossrefType "journal-article" @default.
• W2016308382 hasAuthorship W2016308382A5000653451 @default.
• W2016308382 hasAuthorship W2016308382A5015021993 @default.
• W2016308382 hasAuthorship W2016308382A5020886020 @default.
• W2016308382 hasAuthorship W2016308382A5021558981 @default.
• W2016308382 hasAuthorship W2016308382A5024418476 @default.
• W2016308382 hasAuthorship W2016308382A5033386949 @default.
• W2016308382 hasAuthorship W2016308382A5050936489 @default.
• W2016308382 hasAuthorship W2016308382A5051674313 @default.
• W2016308382 hasAuthorship W2016308382A5052993534 @default.
• W2016308382 hasAuthorship W2016308382A5062520509 @default.
• W2016308382 hasAuthorship W2016308382A5068433367 @default.
• W2016308382 hasAuthorship W2016308382A5069006768 @default.
• W2016308382 hasAuthorship W2016308382A5072408201 @default.
• W2016308382 hasAuthorship W2016308382A5085163310 @default.
• W2016308382 hasConcept C126322002 @default.
• W2016308382 hasConcept C134018914 @default.
• W2016308382 hasConcept C164705383 @default.
• W2016308382 hasConcept C207103383 @default.
• W2016308382 hasConcept C2777698277 @default.
• W2016308382 hasConcept C2778213512 @default.
• W2016308382 hasConcept C2779464278 @default.
• W2016308382 hasConcept C2780400711 @default.
• W2016308382 hasConcept C2780578515 @default.
• W2016308382 hasConcept C44249647 @default.
• W2016308382 hasConcept C500558357 @default.
• W2016308382 hasConcept C511355011 @default.
• W2016308382 hasConcept C555293320 @default.
• W2016308382 hasConcept C71924100 @default.
• W2016308382 hasConceptScore W2016308382C126322002 @default.
• W2016308382 hasConceptScore W2016308382C134018914 @default.
• W2016308382 hasConceptScore W2016308382C164705383 @default.
• W2016308382 hasConceptScore W2016308382C207103383 @default.
• W2016308382 hasConceptScore W2016308382C2777698277 @default.
• W2016308382 hasConceptScore W2016308382C2778213512 @default.
• W2016308382 hasConceptScore W2016308382C2779464278 @default.

• next